Arthritis news and arthritis widget

Results from two Phase 3 studies showed that patients receiving every four week subcutaneous injections of golimumab (CNTO 148) 50 mg or 100 mg, an investigational therapy, experienced significant improvements in physical function, health-related quality of life (HRQOL) and fatigue.

Data from two Phase III studies showed that patients who suffer from the debilitating and painful effects of rheumatoid arthritis (RA) achieved significant improvements in signs and symptoms when treated with ACTEMRA(R) (tocilizumab) alone or in combination with methotrexate compared with methotrexate alone.

UCB announced results from several Phase III clinical trials evaluating CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF (Tumor Necrosis Factor) - presented at the American College of Rheumatology (ACR) Annual Scientific Meeting.

More than half of patients receiving every four week subcutaneous injections of golimumab (CNTO 148) 50 mg and 100 mg, an investigational therapy, experienced sustained improvements in the joint and skin symptoms of active psoriatic arthritis through six months with results sustained through one year.

Results of the REFLEX study1 show that the number of people with rheumatoid arthritis (RA) achieving clinical remission from their disease doubled over three successive treatment courses with MabThera (rituximab) when used in combination with methotrexate (from 8.8% achieving clinical remission* after the first course to 17.6% after the third course).

New Phase III data demonstrate that ACZ885 (canakinumab), a biological drug in development, achieved rapid and long-lasting clinical remission after just one dose in children and adults with a group of rare but potentially life-threatening autoinflammatory diseases called Cryopyrin-Associated Periodic Syndromes (CAPS)1. Due to the long duration of response, patients only needed further treatment every two months1.

Bristol-Myers Squibb Company (NYSE: BMY) today announced at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco results from a 10-month study which showed that ORENCIA® (abatacept), compared to placebo, significantly improved multiple aspects of health-related quality of life (HRQoL): physical and psychosocial well being, pain and sleep quality in juvenile idiopathic arthritis (JIA) patients between the ages 6 and 17 years.

Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a Phase IIIb study in adult patients with early moderate-to-severe erosive rheumatoid arthritis (RA) who had never received previous methotrexate (MTX) treatment. This study showed that ORENCIA® (abatacept) in combination with MTX had significantly more patients achieve a Disease Activity Score 28 using C-reactive protein [DAS28 (CRP)]-defined remission, compared with MTX plus placebo (PBO) (41.4 percent versus 23.

The University of Kentucky Pharmacy and medicine Continuing Education Office (UKPMCE) announced today the launch of the Rheumatoid Arthritis Educational Challenge (RAEC), which will address deficits in the treatment of rheumatic diseases, particularly rheumatoid arthritis (RA).

Title: Rheumatoid Arthritis Rising Among U.S. WomenCategory: health newscreated: 10/28/2008 2:00:00 amlast Editorial review: 10/28/2008